Company intelligence / Profile preview
Quest PharmaTech Inc.
Edmonton, Alberta, Canadaquestpharmatech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Quest PharmaTech is developing Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. The company is also developing Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications, currently in preclinical stage.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Monoclonal antibodySmall molecule drug
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Quest PharmaTech Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quest PharmaTech Inc..